Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Spark Therapeutics, Inc. | spark-20178kq1earnings.htm |
Exhibit 99.1
Spark Therapeutics Reports First Quarter 2017 Financial Results
and Recent Business Progress
Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete
Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported; continuing enrollment targeting participants at earlier stage of disease
PHILADELPHIA, May 9, 2017 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced financial results for the first quarter of 2017 and recent business progress.
“I’m pleased to announce that our work on the rolling BLA for voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease is now complete. The application formally will be submitted to the FDA next week,” said Jeffrey D. Marrazzo, chief executive officer. “We are excited to reach this major milestone, and will now shift our immediate regulatory focus to completing the Marketing Authorization Application submission for Europe by the end of July. Today, we report interim results of our second investigational gene therapy for a retinal disease, SPK-7001 in choroideremia, and that we plan to provide an initial update on the Phase 1/2 trial for SPK-8011 in hemophilia A in July or August 2017.”
Recent highlights
Advanced investigational voretigene neparvovec for the treatment of biallelic RPE65-mediated IRD:
• | Progressed regulatory submissions in U.S. and EU |
◦ | U.S. BLA is complete and ready for submission next week |
Announced interim results of investigational SPK-7001 for choroideremia Phase 1/2 clinical trial:
• | Reported interim safety results for the first 10 participants with later-stage disease |
◦ | No reported product-related serious adverse events (SAEs) and one procedure-related SAE |
• | As of the March 29, 2017 data cutoff, interim efficacy analysis of the first 10 participants in the Phase 1/2 clinical trial did not show consistent and conclusive evidence of effect at the duration of follow-up in later-stage participants |
◦ | However, non-significant differences between the injected and control eye were observed on one or more endpoints in four of the 10 participants in favor of the injected eye |
• | Expanded enrollment of the second dose cohort with focus on participants with earlier-stage disease |
◦ | Three of the five participants already have been enrolled |
Reported updated data from investigational SPK-9001 for hemophilia B Phase 1/2 clinical trial at Hemostasis and Thrombosis Research Society 2017 Scientific Symposium:
• | No SAEs have been reported to date, including no factor IX inhibitors and no thrombotic events |
• | Since vector administration, as of data cutoff of March 24, 2017, among the 10 participants, the annualized infusion rate had been reduced by 99 percent, and the annualized bleeding rate had been reduced by 96 percent |
◦ | Nine of the 10 infused participants had not taken any factor IX concentrates to prevent or control bleeding events |
◦ | Mean steady-state factor IX activity level post-12 weeks treatment for the 10 participants was a sustained 33 percent |
• | Two participants who experienced an asymptomatic, transient elevation in liver enzymes or a decline in FIX activity and received a tapering dose of oral corticosteroids, have completed their steroid taper. Importantly, both participants, now at 14 weeks and eight weeks post-cessation of steroids, have shown stable factor IX activity levels |
◦ | Neither participant has experienced a bleed nor taken factor IX concentrates |
Bolstered organizational capabilities and human capital:
• | Continued preparations for potential introduction of investigational voretigene neparvovec in U.S. and EU |
• | Continued to grow our team across all disciplines, with the number of employees now at more than 240 |
• | Balance sheet remains strong, with $285.4 million in cash and cash equivalents and marketable securities at March 31, 2017 |
Financial results for the quarter ended March 31, 2017
In each of the three months ended March 31, 2017 and 2016, we recognized $1.3 million of revenue associated with our Pfizer collaboration.
Spark Therapeutics’ research and development expenses for the three months ended March 31, 2017 were $32.7 million, compared with $18.2 million for the three months ended March 31, 2016. The $14.5 million increase was due to an $11.4 million increase in internal research and development expenses, primarily due to significantly increased headcount, and an increase of $3.1 million in external research and development, primarily from an increase of $1.3 million in expenses related to studies to support and certain launch preparation activities for voretigene neparvovec, and an increase in our other clinical programs of $1.2 million and $0.6 million related to our other product candidates.
General and administrative expenses for the three months ended March 31, 2017 were $21.4 million, compared with $8.9 million for the three months ended March 31, 2016. The $12.5 million increase was primarily due to an
increase of $6.3 million in salaries and related costs, including stock-based compensation, due to increased headcount, and an increase of $6.2 million in launch preparation activities for voretigene neparvovec, legal and patent expenses, professional fees and other operating costs.
Our net loss applicable to common stockholders for the three months ended March 31, 2017 was $52.3 million, or $1.70 basic and diluted net loss per common share, as compared with a net loss applicable to common stockholders of $25.6 million, or $0.95 basic and diluted net loss per common share for the three months ended March 31, 2016.
As of March 31, 2017, we had cash and cash equivalents and marketable securities of $285.4 million, with 31.1 million shares outstanding.
Conference call details
Spark Therapeutics will host a conference call and audio webcast, today, Tuesday, May 9, at 8:30 a.m. ET, to discuss corporate and financial results for the quarter that ended March 31, 2017. The call can be accessed by dialing the numbers below or by visiting the “Investors” section at www.sparktx.com.
U.S. Dial-in Number: (855) 851-4526
International Dial-in Number: (720) 634-2901
Passcode: 13840065
A replay of the call will be available for one week following the call by dialing the numbers below or also available on our website.
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Passcode: 13840065
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Cautionary note on forward-looking statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's product candidates, including voretigene neparvovec, SPK-7001, SPK-9001 and SPK-8011. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that: (i) our BLA being submitted to the FDA may not be accepted, or, if accepted, may not be approved; (ii) the data from our Phase 3 clinical trial of voretigene neparvovec may not support labeling for all biallelic RPE65 mutations other than Leber congenital amaurosis (LCA); (iii) the improvements in functional vision demonstrated by voretigene neparvovec in our clinical trials may not be sustained over extended periods of time; (iv) interim data from our SPK-7001 Phase 1/2 clinical trial, including data to be generated from our recently expanded cohort, may not support further development of this product candidate; (v) preclinical results for our product candidate, SPK-8011, for hemophilia A may not translate to humans in clinical trials; (vi) our lead SPK-FIX product candidate, SPK-9001, may not produce sufficient data in our Phase 1/2 clinical trial to warrant further development; and (vii) any one or more of our product candidates in preclinical or clinical development will not successfully be developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings we make with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Spark undertakes no duty to update this information unless required by law.
Investor Contact: Media Contact:
Ryan Asay Monique da Silva
Ryan.asay@sparktx.com Monique.dasilva@sparktx.com
(215) 239-6424 (215) 282-7470
Spark Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
December 31, 2016 | March 31, 2017 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 58,923,097 | $ | 27,495,174 | |||
Marketable securities | 237,242,655 | 226,199,646 | |||||
Other receivables | 16,780,917 | 5,946,802 | |||||
Prepaid expenses and other current assets | 1,647,008 | 3,713,708 | |||||
Total current assets | 314,593,677 | 263,355,330 | |||||
Marketable securities | 21,900,129 | 31,700,984 | |||||
Property and equipment, net | 19,794,306 | 23,097,630 | |||||
Acquired in-process research and development | 15,490,000 | 14,950,531 | |||||
Goodwill | 1,160,104 | 1,119,564 | |||||
Other assets | 924,579 | 853,510 | |||||
Total assets | $ | 373,862,795 | $ | 335,077,549 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 9,928,737 | $ | 14,021,116 | |||
Accrued expenses and other | 13,826,920 | 9,097,776 | |||||
Current portion of long-term debt | 302,013 | 304,473 | |||||
Current portion of deferred rent | 771,196 | 1,140,735 | |||||
Current portion of deferred revenue | 5,168,674 | 5,168,674 | |||||
Total current liabilities | 29,997,540 | 29,732,774 | |||||
Long-term debt | 1,224,003 | 1,146,956 | |||||
Long-term deferred rent | 7,498,419 | 11,086,281 | |||||
Long-term deferred revenue | 3,865,885 | 2,591,418 | |||||
Deferred tax liability | 1,000,235 | 965,401 | |||||
Total liabilities | 43,586,082 | 45,522,830 | |||||
Stockholders’ equity: | |||||||
Preferred stock, $0.001 par value. Authorized, 5,000,000 shares; no shares issued or outstanding | — | — | |||||
Common stock, $0.001 par value. Authorized, 150,000,000 shares; 30,873,430 shares issued and 30,864,224 shares outstanding at December 31, 2016; 31,086,809 shares issued and 31,077,603 shares outstanding at March 31, 2017 | 30,874 | 31,087 | |||||
Additional paid-in capital | 583,973,682 | 596,436,232 | |||||
Accumulated other comprehensive loss | (794,296 | ) | (1,689,721 | ) | |||
Treasury stock, at cost, 9,206 shares at December 31, 2016 and March 31, 2017 | (552,636 | ) | (552,636 | ) | |||
Accumulated deficit | (252,380,911 | ) | (304,670,243 | ) | |||
Total stockholders’ equity | 330,276,713 | 289,554,719 | |||||
Total liabilities and stockholders’ equity | $ | 373,862,795 | $ | 335,077,549 | |||
Spark Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
Three months ended March 31, | |||||||
2016 | 2017 | ||||||
Revenues | $ | 1,288,628 | $ | 1,274,467 | |||
Operating expenses: | |||||||
Research and development | 18,251,900 | 32,735,033 | |||||
General and administrative | 8,873,861 | 21,413,818 | |||||
Total operating expenses | 27,125,761 | 54,148,851 | |||||
Loss from operations | (25,837,133 | ) | (52,874,384 | ) | |||
Interest income | 260,422 | 585,052 | |||||
Net loss | $ | (25,576,711 | ) | $ | (52,289,332 | ) | |
Basic and diluted net loss per common share | $ | (0.95 | ) | $ | (1.70 | ) | |
Weighted average basic and diluted common shares outstanding | 26,807,380 | 30,771,867 | |||||
# # #